The EQ-5D-5L Predicts Treatment Outcomes and Provides Added Value to the R-IPSS in Patients with MDS, CMML or AML Treated within the Austrian Azacitidine Registry - a Prospective Cohort Study By the AGMT Study Group

▪ Background The EuroQuol 5 Dimension (EQ5D) is a validated tool to assess health-related quality of life (HRQoL). The International Prognostic Scoring System (IPSS) and the revised IPSS (R-IPSS) are the gold standards of prognostication in patients (pts) with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). The EQ5D is the most used tool for patient reported outcome measures but is underused in MDS, CMML or AML, with only one report on the use of the updated 5 level (5L) published to date (Yu H, Qual Life Res 2021, 855). Aims 1) Compare HRQoL of pts with MDS, CMML or AML with a German population norm (Grochtdreis T, Eur J Health Econ 2019, 933) matched by age, sex and no. of comorbidities. 2) Assess the impact of baseline HRQoL on azacitidine (AZA) treatment (trt) outcomes. 3) Longitudinal analyses of EQ-5D/lab value pairs per AZA cycle. Methods Pts treated within the Austrian Azacitidine Registry were analyzed (NCT01595295, data cut-off 13 Dec 20). EQ5D and lab values were assessed at the start of AZA trt cycles. The EQ5D-5L German value set (Ludwig K, Pharmacoeconomics 2018, 663) and the reverse crosswalk tool provided by EuroQol were used for calculation of the EQ5D-index. Baseline characteristics with univariate p